Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Concise Method
Treatment kinase inhibitors and siRNA transfection
Request a Protocol
Ask a
question
Favorite
Cells were pretreated with various inhibitors (Sigma-Aldrich) such as NF-κB-specific inhibitor: Bay11-7085 (20 μM), STAT3-specific inhibitor: S3I-201 (20 μM), and ERK1/2-specific inhibitor: PD98059 (20 μM). After 1 h, the cells were treated and co-cultured with METH for 24 h. Cells were transfected with control siRNA (Cat no: sc-37007, Santa Cruz, CA, USA) and ERK-MAPK siRNA (Cat no: 6560, Cell Signaling Technology, MA, USA) using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s instruction.
Copyright and License information: The Author(s). ©2017
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
